Article Text

Download PDFPDF
The quest for biomarker discovery in pulmonary arterial hypertension: the right takes lessons from the left
  1. Bradley A Maron1,2
  1. 1Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
  2. 2Department of Cardiology, Boston VA Healthcare System, Boston, Massachusetts, USA
  1. Correspondence to Dr Bradley Maron, 77 Ave. Louis Pasteur, NRB Room 0630-N, Boston, MA 02115, USA; bmaron{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Pulmonary arterial hypertension (PAH) is a severe form of cardiopulmonary disease that is characterised by plexogenic, hypertrophic and fibrotic remodelling of distal pulmonary arterioles. Although abnormal pulmonary vasoreactivity and increased vasoconstriction occur in the setting of these maladaptive changes to blood vessel phenotype, the 5-year mortality rate for PAH remains elevated even in the contemporary era of pulmonary vasodilator therapy.1 An obvious approach to address this is the development of novel therapeutics that target the pathogenesis of vascular remodelling. However, accumulating clinical trial data also suggest that treatment timing and drug class selection when based on clinical status2 and disease subtype,3 respectively, are important factors for optimising therapeutic efficacy and reducing PAH clinical events. Nonetheless, point-of-care risk stratification methods to guide initiation or escalation of treatment in PAH are limited currently to elaborate scoring systems that require invasive haemodynamic data, or metrics such as changes in 6-min walk distance and functional class that hinge on subjective assessment or are of controversial utility in clinical practice.4

This dilemma illustrates a critical, but incompletely met, need in the field of clinical pulmonary vascular disease: the identification …

View Full Text


  • Funding This work was supported by National Institutes of Health (K08HL111207-01A1), American Heart Association (AHA 15GRNT25080016), Cardiovascular Medical Research and Education Foundation (CMREF) and the Klarman Foundation (Boston, Massachusetts, USA) at Brigham and Women's Hospital.

  • Competing interests BAM receives funding from Gilead Sciences Inc. to study pulmonary hypertension.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles